ValuEngine downgraded shares of Eli Lilly And Co (NYSE:LLY) from a buy rating to a hold rating in a research report released on Tuesday.
A number of other research firms have also weighed in on LLY. Guggenheim began coverage on shares of Eli Lilly And Co in a research note on Monday, October 8th. They set a buy rating for the company. Zacks Investment Research upgraded shares of Eli Lilly And Co from a hold rating to a buy rating and set a $129.00 price objective for the company in a research note on Tuesday, October 9th. BMO Capital Markets raised shares of Eli Lilly And Co from a market perform rating to an outperform rating and raised their price target for the company from $107.00 to $130.00 in a report on Thursday, October 4th. JPMorgan Chase & Co. set a $123.00 price target on shares of Eli Lilly And Co and gave the company a buy rating in a report on Friday, October 5th. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $128.00 price target on shares of Eli Lilly And Co in a report on Wednesday, October 17th. Nine research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $111.19.
NYSE:LLY opened at $112.21 on Tuesday. The stock has a market cap of $116.23 billion, a price-to-earnings ratio of 26.22, a PEG ratio of 1.75 and a beta of 0.29. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.09. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $116.61.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.01%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is presently 52.57%.
In other news, SVP Alfonso G. Zulueta sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total transaction of $637,860.00. Following the sale, the senior vice president now owns 55,224 shares of the company’s stock, valued at approximately $5,870,863.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 151,793 shares of the firm’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $103.23, for a total transaction of $15,669,591.39. Following the sale, the insider now directly owns 120,555,804 shares in the company, valued at approximately $12,444,975,646.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,881,684 shares of company stock worth $133,274,076. Insiders own 0.11% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC boosted its holdings in shares of Eli Lilly And Co by 172.9% in the second quarter. FMR LLC now owns 1,188,301 shares of the company’s stock worth $101,398,000 after buying an additional 752,864 shares during the last quarter. We Are One Seven LLC purchased a new position in shares of Eli Lilly And Co in the third quarter worth approximately $1,084,000. Greenleaf Trust boosted its holdings in shares of Eli Lilly And Co by 37.7% in the second quarter. Greenleaf Trust now owns 9,815 shares of the company’s stock worth $838,000 after buying an additional 2,686 shares during the last quarter. First American Bank purchased a new position in shares of Eli Lilly And Co in the third quarter worth approximately $7,863,000. Finally, Peoples Financial Services CORP. boosted its holdings in shares of Eli Lilly And Co by 4.7% in the third quarter. Peoples Financial Services CORP. now owns 16,825 shares of the company’s stock worth $1,806,000 after buying an additional 750 shares during the last quarter. 76.17% of the stock is currently owned by institutional investors.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Diversification Important in Investing
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.